Back to top
more

Pacific Biosciences of California (PACB)

(Delayed Data from NSDQ)

$2.44 USD

2.44
10,605,080

+0.27 (12.44%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $2.45 +0.01 (0.41%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Pacific Biosciences of California (PACB) closed the most recent trading day at $1.65, moving -1.5% from the previous trading session.

Reasons to Retain PacBio (PACB) Stock in Your Portfolio

by Zacks Equity Research

PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.

Pacific Biosciences of California, Inc. (PACB) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Zacks.com users have recently been watching Pacific Biosciences (PACB) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

PacBio (PACB) Q1 Earnings In Line, Adjusted Gross Margin Up

by Zacks Equity Research

PacBio (PACB) reports growth in Product revenues in the first quarter of 2024. However, Instruments revenues decline year over year due to lower shipment of Revio units.

Pacific Biosciences (PACB) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Pacific Biosciences (PACB) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Pacific Biosciences of California (PACB) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0% and 0.08%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of -22.22% and 2.63%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Soft Instrument Orders Likely to Hurt PacBio's (PACB) Q1 Earnings

by Zacks Equity Research

Despite strength in Revio and Onso platforms, an increasing number of customers delaying instrument purchases is likely to have dampened PacBio's (PACB) top line in the first quarter.

Investors Heavily Search Pacific Biosciences of California, Inc. (PACB): Here is What You Need to Know

by Zacks Equity Research

Pacific Biosciences (PACB) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Cigna (CI) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Cigna (CI) delivered earnings and revenue surprises of 4.86% and 1.07%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Here's Why Pacific Biosciences (PACB) is Poised for a Turnaround After Losing -63.44% in 4 Weeks

by Zacks Equity Research

Pacific Biosciences (PACB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Pacific Biosciences (PACB) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Pacific Biosciences (PACB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

PacBio (PACB) Preliminary Q1 Revenues Dampened by Purchase Delays

by Zacks Equity Research

PacBio's (PACB) revenue growth in the first quarter is likely to have been hampered by an increasing number of customers delaying instrument purchases and softness in consumable shipments.

Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now

by Zacks Equity Research

PacBio's (PACB) strong product demand and top-line growth raise optimism about the stock.

PacBio's (PACB) New Panel to Aid Its Clinical Research Solution

by Zacks Equity Research

PacBio (PACB) announces the PureTarget repeat expansion panel, which is the HiFi long-read sequencing that supports comprehensive analysis of 20 genes associated with neurological diseases.

PacBio (PACB) Q4 Earnings Beat, Adjusted Gross Margin Down

by Zacks Equity Research

PacBio (PACB) witnesses strong revenue growth in the fourth quarter, partly aided by customers' continued product transition to the Revio system.

Pacific Biosciences (PACB) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Pacific Biosciences (PACB) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Pacific Biosciences of California (PACB) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Pacific Biosciences (PACB) delivered earnings and revenue surprises of 12.90% and 0.20%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Debanjana Dey headshot

Medical Products Stocks' Earnings Due on Feb 15: WST, ITGR & More

by Debanjana Dey

Medical Products companies' quarterly results are likely to reflect strength in customer demand. Let's see how ITGR, WST, AMN and PACB are placed ahead of their earnings releases.

PacBio's (PACB) New Kits to Boost Its Revio Sequencing System

by Zacks Equity Research

PacBio's (PACB) new library preparation kits are likely to boost Revio's long-read sequencing systems by reducing cost and workflow time.

PacBio's (PACB) New PanDNA Kit Ready to Boost DNA Extraction

by Zacks Equity Research

PacBio's (PACB) new offering, PanDNA kit, is likely to help researchers effectively extract DNA optimized for HiFi sequencing. This versatile Nanobind kit is expected to be available in February 2024.

PacBio (PACB) Preliminary Q4 Revenues Boosted by Revio Sales

by Zacks Equity Research

PacBio's (PACB) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its sequencing systems.

CVRx (CVRX) Moves 24.2% Higher: Will This Strength Last?

by Zacks Equity Research

CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now

by Zacks Equity Research

PacBio's (PACB) product development activities raise optimism about the stock.

Shockwave Medical (SWAV) Down 1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Shockwave Medical (SWAV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.